WO2020089286A1 - Cyclodextrin-based formulation of a bcl-2 inhibitor - Google Patents

Cyclodextrin-based formulation of a bcl-2 inhibitor Download PDF

Info

Publication number
WO2020089286A1
WO2020089286A1 PCT/EP2019/079644 EP2019079644W WO2020089286A1 WO 2020089286 A1 WO2020089286 A1 WO 2020089286A1 EP 2019079644 W EP2019079644 W EP 2019079644W WO 2020089286 A1 WO2020089286 A1 WO 2020089286A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
cyclodextrin
compound
cancer
Prior art date
Application number
PCT/EP2019/079644
Other languages
French (fr)
Inventor
Caroline CHEMIN
Thuy TRAN THU
Jean-Manuel Pean
Maïa CHANRION
Original Assignee
Les Laboratoires Servier
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CR20210210A priority Critical patent/CR20210210A/en
Priority to PE2021000642A priority patent/PE20211738A1/en
Priority to US17/288,721 priority patent/US20210353633A1/en
Priority to EA202191144A priority patent/EA202191144A1/en
Priority to SG11202103965TA priority patent/SG11202103965TA/en
Priority to MX2021004864A priority patent/MX2021004864A/en
Priority to CA3117511A priority patent/CA3117511A1/en
Application filed by Les Laboratoires Servier, Novartis Ag filed Critical Les Laboratoires Servier
Priority to AU2019373373A priority patent/AU2019373373B2/en
Priority to CN201980070474.4A priority patent/CN112912108A/en
Priority to JOP/2021/0079A priority patent/JOP20210079A1/en
Priority to KR1020217016354A priority patent/KR20210102886A/en
Priority to BR112021007987-4A priority patent/BR112021007987A2/en
Priority to EP19801728.7A priority patent/EP3873529A1/en
Priority to JP2021523227A priority patent/JP2022506069A/en
Publication of WO2020089286A1 publication Critical patent/WO2020089286A1/en
Priority to PH12021550878A priority patent/PH12021550878A1/en
Priority to DO2021000073A priority patent/DOP2021000073A/en
Priority to CONC2021/0005221A priority patent/CO2021005221A2/en
Priority to IL282688A priority patent/IL282688A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising 5-(5-chloro-2- ⁇ [(3.S')-3- Onorphol i n-4-yl methyl )-3,4-dihydroisoquinolin-2( 1 //)-yl]carbonyl ⁇ phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 //-pyrrole-3- carboxamide, referred to herein as‘Compound A’, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
  • the invention relates to a solid pharmaceutical composition comprising Compound A and a cyclodextrin, and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. Furthermore, the invention relates to the use of such compositions for the treatment of cancer.‘Compound A’ as used herein optionally includes the pharmaceutically acceptable salts thereof.
  • solubilize poorly soluble compounds for parenteral administration There are different ways to solubilize poorly soluble compounds for parenteral administration. Typical approaches are the optimization of the pH or the use of co-solvents (e.g. PEG300, PEG400, propylene glycol, or ethanol). If these approaches are, for any reason, not feasible, the use of surfactants may be considered (e.g. Tween® 80 or KolliphorTM ELP). However, these types of surfactants are frequently associated with adverse effects and not always able to solubilize the compounds of interest at targeted concentrations. Cyclodextrins are established as safe solubilizing agents, yet with limitations as they are not effective solubilizers for all compounds.
  • the aim of the current invention is to provide a composition which can conveniently be used to solubilize and parenterally deliver Compound A at targeted concentrations for having clinical efficacy.
  • a pharmaceutical composition for Compound A which is safe and efficacious.
  • Further aims are to provide a composition which is stable in the relevant conditions and containers, and which enables administration of an appropriate dose of Compound A over a reasonable timescale.
  • the composition should be able to be manufactured by a reliable and robust process for the preparation of parenteral dosage forms.
  • the present invention provides a composition comprising Compound A and a cyclodextrin, suitable for parenteral administration to patients.
  • administration is by intravenous injection or infusion.
  • the invention further provides a solid cyclodextrin-based composition which can be dissolved in one or more solvents shortly before administration to the patient, in order to provide the composition suitable for parenteral administration.
  • the solid cyclodextrin-based composition according to the invention is placed in an aqueous solution.
  • Compound A is solubilized by means of a cyclodextrin.
  • the invention provides a composition comprising Compound A which has an optimal physical stability; for example the precipitation of components is avoided when the solid composition is placed in an aqueous solution and further diluted in a glucose solution and when the resulting pharmaceutical composition is injected in the plasma.
  • the invention provides a pharmaceutical cyclodextrin-based composition comprising Compound A, which is chemically and physically stable.
  • drug/cyclodextrin complexes have tendency to form large and visible particles (Saokham el al, Molecules 2018 23 page 1161). These solid microparticles obviously prevent a sterile filtration operation.
  • the drug/cyclodextrin solutions according to the invention remain perfectly clear and can be very easily filtrated on 0.2 pm filter.
  • the invention provides a solid pharmaceutical composition having an acceptable reconstitution time in solvents for injection (more preferably in water for injection), and thus allowing ease of use for the preparation of the pharmaceutical composition that will be parenterally delivered.
  • the invention provides a pharmaceutical cyclodextrin-based composition which enables a fast solubilisation and a good distribution of Compound A after intravenous administration.
  • Figure 1 shows the efficacy of Compound A in a cyclodextrin-based formulation after 15 and 40 mg/kg administrated i.v. once a week over two weeks in RS4;l l grafted female SCID mice.
  • Figure 2 shows the tolerability of Compound A in a cyclodextrin-based formulation after 15 and 40 mg/kg administrated i.v. once a week over two weeks in RS4;l l grafted female SCID mice. Body weight loss is measured versus time after treatment.
  • Compound A means 5-(5-chloro-2- ⁇ [(3.S')-3-(morphol in-4-yl methyl )-3, 4- dihydroisoquinolin-2(l )-yl]carbonyl ⁇ phenyl)-/V-(5-cyano-l, 2-dimethyl- l -pyrrol-3-yl)- /V-(4-hydroxyphenyl)- 1 ,2-dimethyl- l -pyrrole-3-carboxamide.
  • Compound A, H 2 S0 4 means that 5-(5-chloro-2- ⁇ [(3.S')-3-(morphol in-4-yl methyl )-3, 4- dihydroisoquinolin-2(l )-yl]carbonyl ⁇ phenyl)-/V-(5-cyano- 1 ,2-dimethyl- 1 /-pyriol -3-yl )- V-(4-hydroxyphenyl)-l, 2-dimethyl- l -pyrrole-3-carboxamide is in the form of a hydrogen sulfate salt.
  • Free molecule and‘free base’ are used interchangeably herein and refer to Compound A when not in salt form.
  • the cyclodextrin described herein is a natural or derived cyclodextrin.
  • Natural cyclodextrins comprise three well-known industrially produced (major and minor) cyclic oligosaccharides. The most common natural cyclodextrins are a, b, and g consisting of 6, 7, and 8 glucopyranose units.
  • Derived cyclodextrins include hydroxyalkylated cyclodextrins selected from the group consisting of hydroxyethyl cyclodextrin, hydroxypropyl cyclodextrin and hydroxybutyl cyclodextrin.
  • the cyclodextrin is the b-cyclodextrin itself or its derivatives.
  • the derivatives herein mean b-cyclodextrins having various substituents, including methyl- b-cyclodextrin, ethyl ⁇ -cyclodextrin, (2- hydroxypropyl)-P-cyclodextrin, (3-hydroxypropyl)-P-cyclodextrin, (2-hydroxyethyl)-P- cyclodextrin, carboxymethyl-P-cyclodextrin, carboxymethyl-ethyl-P-cyclodextrin, diethyl- b-cyclodextrin, dimethyl- b-cyclodextrin, trimethyl-P-cyclodextrin, glucosyl-b- cyclodextrin, hydroxybutenyl-P-cyclodextrin, maltosyl-P-cyclodextrin, randomly methyl
  • 2- hydroxypropyl-Y-cyclodextrin can be used in the present invention.
  • Derived cyclodextrins also include polymerized cyclodextrins, which are high molecular weight compounds, either water-soluble or insoluble.
  • the examples of polymerized cyclodextrins are soluble anionic //-cyclodextrin polymer, soluble y-cyclodextrin polymer, and epichlorohydrin b- cyclodextrin polymer.
  • ‘a-cyclodextrin’,‘b-cyclodextrin’ and‘y-cyclodextrin’ are also named‘alfadex’,‘betadex’, and‘gammadex’, respectively.
  • ⁇ R- b-cyclodextrm is also named‘hydroxypropyl- b-cyclodextrin’ or‘2-hydroxypropyl- b-cyclodextrin’ or ‘hydroxypropylbetadex’.
  • the HP- b-cyclodextrin is marketed with the following product names: CavitronTM W7HP7 (typical degree of substitution: 6.0-8.0 ; approximate molecular weight: 1520), CavitronTM W7HP5 (typical degree of substitution: 4.1-5.1 ; approximate molecular weight: 1410), KleptoseTM HPB or KleptoseTM HP.
  • SBE- b-cyclodextrin is also named‘sodium sulfobutylether- b-cyclodextrm’ or‘betadex sulfobutyl ether sodium’.
  • the SBE- b-cyclodextrin is marketed with the following product names: DexsolveTM or CaptisolTM.
  • the pharmaceutical composition described herein is, in particular, a pharmaceutical cyclodextrin-based composition.
  • a ‘pharmaceutical cyclodextrin-based composition’ means a composition comprising a cyclodextrin, which is suitable for pharmaceutical administration.
  • TPGS means d-a-tocopheryl polyethylene glycol succinate or tocopher solan. It is a water-soluble form of vitamin E (a- tocopherol).
  • Tonicity adjusting agent means a pharmaceutically acceptable compound which can be added to a formulation to make it isotonic with human plasma.
  • Tonicity adjusting agents include for example dextrose, glucose, mannitol, sucrose, lactose, trehalose, glycerine and NaCl, in particular sucrose or glycerine, more particularly sucrose.
  • Tonicity is the ‘effective osmolality’ and is equal to the sum of the concentrations of the solutes which have the capacity to exert an osmotic force across the membrane.
  • Parenteral formulations should be isotonic with blood plasma. Tonicity adjusting agents are well known to the skilled person.
  • A‘buffer’ is used to prevent changes in the pH of a solution, and suitable examples are well-known to the skilled formulator.
  • Container means an ampoule or vial with rubber stopper and cap, single or double chamber syringe, infusion bag or bottle made from polymeric materials or glass, suitable for housing compositions for parenteral administration. It also includes any vessel for holding liquids.
  • solvent is a solvent used for the reconstitution of a pharmaceutical composition suitable for parenteral administration, starting from a solid pharmaceutical composition.
  • the solid pharmaceutical composition is preferably a lyophilisate.
  • the solvent is water.
  • the water used is water for injection.
  • the term‘comprising’ means‘including’, and is not intended to exclude the presence of any additional component, unless the context suggests otherwise, for example when the components together sum to 100 %.
  • the term‘treat’,‘treating’ or‘treatment’ of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e ., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, ‘treat’, ‘treating’ or ‘treatment’ refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • ‘treat’, ‘treating’ or ‘treatment’ refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • a “therapeutically effective amount of the composition” means an effective amount of the composition according to the invention containing an effective dose of active principle to elicit a therapeutic benefit for the patient.
  • the dose of Compound A administered according to the invention is from 5 mg to 1000 mg (expressed as free base).
  • a solid pharmaceutical composition comprising Compound A which is 5-(5- chloro-2- ⁇ [(35 , )-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(l /)-yl]carbonyl ⁇ phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 H- pyrrole-3-carboxamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
  • a solid pharmaceutical composition according to El wherein Compound A is in the form of a hydrogen sulfate salt.
  • E4. A solid pharmaceutical composition according to any of embodiments El to E3, wherein the cyclodextrin is a sodium sulfobutylether-P-cyclodextrine (SBE- b- cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin).
  • the weight/weight ratio between the HP- b-cyclodextrin and Compound A is 10 : 1 for the solid pharmaceutical compositions according to the invention.
  • the pharmaceutically acceptable excipient is a surfactant.
  • a pharmaceutical composition comprising Compound A which is 5-(5-chloro-2- ⁇ [(35 , )-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(l//)-yl]carbonyl ⁇ phenyl)-/V-(5- cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 //-pyrrole-3- carboxamide, or a pharmaceutically acceptable salt thereof, a cyclodextrin and one or more solvents.
  • the pharmaceutical composition further comprises a surfactant.
  • the pharmaceutical composition according to E17 having a pH value comprised between 2.8 and 3.2, more particularly the pH value is comprised between 2.9 and 3.1.
  • E19 The pharmaceutical composition according to E17 having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5.
  • E20 The pharmaceutical composition according to any of embodiments E14 to E19, wherein the cyclodextrin is a sodium sulfobutylether-P-cyclodextrin (SBE- b-cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin).
  • SBE- b-cyclodextrin sodium sulfobutylether-P-cyclodextrin
  • HP- b-cyclodextrin HP- b-cyclodextrin
  • E21 The pharmaceutical composition according to E20, wherein the sulfobutylether-b- cyclodextrin is selected from DexsolveTM and CaptisolTM.
  • cyclodextrin is a HP- b-cyclodextrin, more particularly CavitronTM W7HP7, CavitronTM W7HP5, KleptoseTM HPB or KleptoseTM HP.
  • E23 The pharmaceutical composition according to E22, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is at least 5 : 1. In another embodiment, the weight/weight ratio between the HP- b-cyclodextrin and Compound A is at least 10 : 1 for the pharmaceutical compositions according to the invention.
  • E24 The pharmaceutical composition according to E23, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is 5 : 1. In another embodiment, the weight/weight ratio between HP- b-cyclodextrin and Compound A is 10 : 1 for the pharmaceutical compositions according to the invention.
  • E27 The pharmaceutical composition according to any of embodiments E22 to E26 having a concentration comprised between 50 and 300 mg/mL of HP- b-cyclodextrin.
  • E28 The pharmaceutical composition according to E27 having a concentration of 200 mg/mL of HP- b-cyclodextrin.
  • E29 The pharmaceutical composition according to any of embodiments E22 to E26 having a concentration of 20 mg/mL of Compound A, free base.
  • E30 The pharmaceutical composition according to any of embodiments E14 to E29, further comprising a tonicity adjusting agent.
  • the pharmaceutical composition further comprises water.
  • the pharmaceutical composition according to E14 comprising ‘Compound A, H 2 S0 4 ’ and CavitronTM W7HP5, and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5.
  • the solvent used in the pharmaceutical composition is water.
  • the pharmaceutical composition according to E14 comprising‘Compound A, H 2 S0 4 ’, CavitronTM W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4,
  • E44 The pharmaceutical composition according to E43, for infusion or intravenous injection.
  • a process for preparing a pharmaceutical composition according to E14 suitable for parenteral administration comprising the dissolution of a solid pharmaceutical composition as defined in El to El 3 in a solvent, more particularly in water.
  • a process according to E45 comprising an additional step of dilution with an infusion solution, more particularly with a solution of 5% Glucose.
  • E48 A method of modulating Bcl-2 receptor activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the composition according to any of embodiments E14 to E44.
  • E49. A method of treating cancer, comprising administering to the subject a therapeutically effective amount of the composition according to any of embodiments E14 to E44.
  • E50 A method according to E49, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
  • the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for
  • E51 A method according to E50, wherein the cancer is selected from non-Hodgkin's B- cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, more particularly non-Hodgkin's B-cell lymphoma, multiple myeloma and acute myeloid leukaemia.
  • E52 A method according to any of embodiments E48 to E51, wherein the composition according to any of embodiments E14 to E36, is administered once weekly.
  • cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the cesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia,
  • a pharmaceutical composition for use according to embodiment E54, wherein said cancer is selected from non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, more particularly non-Hodgkin's B-cell lymphoma, multiple myeloma and acute myeloid leukaemia.
  • E57 The use according to E56, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer, in particular non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, and more particularly non-Hodgkin's B
  • a lyophilisate comprising Compound A and CavitronTM W7HP5, which can be dissolved in a solvent, preferably water, shortly before administration to produce a transparent composition.
  • the previous solution can be further diluted with a solution of Glucose 5%.
  • this is achieved by transferring the pharmaceutical composition comprising Compound A and CavitronTM W7HP5 as described herein into a 250 mL glucose bag.
  • the preparation of the solid pharmaceutical composition according to the invention may comprises a step of adjustment of the pH of the initial solution before drying.
  • the pH of the solution is adjusted by adding drop by drop, either a HC1 solution or a NaOH solution, depending on the concentration of Compound A contained in the initial solution.
  • the objective of these studies is to define the solubility at saturation of Compound A with the aim of formulating an injectable solution characterised by a concentration of active ingredient which is sufficiently high to meet the therapeutic needs of an administration in humans.
  • an injectable solution characterised by a concentration of active ingredient which is sufficiently high to meet the therapeutic needs of an administration in humans.
  • the permitted daily exposure for the HR-b- cyclodextrin amounts to 320 mg/kg/day.
  • SBE ⁇ -cyclodextrin type sulfobutyl ether b-cyclodextrin
  • HR-b-cyclodextrin hydroxypropyl b -cyclodextrin
  • SBE-b- cyclodextrin tested is DexsolveTM marketed by Cyclolab
  • HR-b- cyclodextrins tested are CavitronTM W7HP7 and CavitronTM W7HP5 marketed by Wacker
  • KleptoseTM HP and KleptoseTM HPB marketed by Roquette;
  • the 5 carriers permitting substantial solubilisation of Compound A are: CavitronTM W7HP5 ⁇ KleptoseTM HPB > KleptoseTM HP ⁇ DexsolveTM ⁇ CavitronTM W7HP7 > PEG400 > PEG400/EtOH/0.9% NaCl (40/10/50).
  • the solubilities in those media are between 10 and 30 mg/mL after 24 hours' stirring.
  • CavitronTM W7HP5 and KleptoseTM HPB are the most effective carrier for solubilising Compound A and permitting the manufacture of solutions with a sufficient content of active ingredient for the purpose of parenteral administration in humans.
  • the solutions wherein the molar ratio between the HR-b-cyclodextrin and Compound A is 5 : 1 are a compromise between drug loading and content of HR-b-cyclodextrin in accordance with the permitted daily exposure. Higher ratios are also acceptable within the limit of the permitted daily exposure.
  • 0.75 g of sodium acetate trihydrate (NaC 2 H 3 0 2 , 3H 2 0) is introduced into a 250 mL graduated flask. 3.5 mL of 2 N acetic acid solution (produced from glacial acetic acid) are added. The volume is then made up to 250 mL by means of 0.9% NaCl solution, and the whole is then stirred. The pH is then adjusted to 4 by means of 1 N HC1 solution.
  • a precipitate is visually observed from pH 3.2.
  • the objective of this study is to evaluate the possible precipitation of Compound A formulated in a HR-b-cyclodextrin (i.e. CavitronTM W7HP5) or in a PEG400/EtOH/0.9% NaCl mixture (in the presence or absence of TPGS) in canine plasma.
  • a HR-b-cyclodextrin i.e. CavitronTM W7HP5
  • a PEG400/EtOH/0.9% NaCl mixture in the presence or absence of TPGS
  • the pH measured after dilution in the plasma was between 7.5 and 8.
  • EXAMPLE 4 Study of the physical stability of lvophilisates made from Compound A 5 and a HP-B-cvclodextrin in the presence or absence of other excipients
  • the osmolality of the solutions containing between 10 to 20 mg/mL of glucose, mannitol, sucrose, trehalose or sorbitol is greater than 400 mOsm/kg, while that of the solutions without glucose is approximately 300 mosm/kg.
  • the fact of omitting the glucose from the formulation reduces the osmolality significantly.
  • the osmolality of the solutions without glucose is acceptable for the purpose of parenteral administration.
  • the lyophilisates obtained, with and without glucose, mannitol, sucrose, trehalose or sorbitol, have robust physical properties, namely a good cake appearance and an acceptable reconstitution time.
  • the lyophilisates are prepared in 20 mL vials in which it will be possible to reconstitute the solution to be administered by the parenteral route. They are obtained by lyophilisation of a 20% CavitronTM W7HP5 solution containing a dose of 20 mg/mL of Compound A (free base). Procedure
  • the resulting lyophilisate is intended to be used for the preparation of a pharmaceutical composition for parenteral administration.
  • Further experiments show that the pH of the pharmaceutical compositions dosed at 20 mg/mL of Compound A after reconstitution in water starting from the above lyophilisate is mostly identical to the pH of the solution observed before the lyophilisation step, i.e. comprised between 2.9 and 3.1. Consequently the pH specification of the drug product has been set up between 2.5 and 3.5.
  • the aim of this study is to determine the pH for 7 different concentrations of Compound A solubilised in CavitronTM W7H5 and diluted in a bag of 250 mL of glucose 5% (G5 solution), and then to check visually that there has been no precipitation at the different concentrations tested (12 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1 g of active ingredient in 250 mL of G5).
  • the Compound A used is in the form of a hydrogen sulfate salt. Invisible particulate contamination of the solutions was also controlled by light obscuration technique.
  • a mother solution containing a dose of 200 mg/mL of CavitronTM W7H5 and 20 mg/mL of Compound A (expressed for the free base) is prepared by dissolving a lyophilisate as described in Example 5 in the necessary amount of water. The solution so obtained is then diluted by means of glucose 5% solution (G5).
  • the pH of the solutions obtained is measured and the appearance of the solutions is observed.
  • the pH is increased using NaOH 0.01N solution until a precipitation is observed.
  • the pH of G5 solution is between 3.02 and 4.353.
  • Compound A solubilised by means of a CavitronTM W7H5 solution do not precipitate when diluted in G5 solution for concentrations between 12 and 1000 mg/250 mL of G5 solution.
  • Compound A as formulated in the present invention can therefore be reconstituted in water and diluted in a bag of 250 mL of glucose 5% over a wide range of concentrations before being administered by the parenteral route.
  • the rate of sub-visible particles detected using the light obscuration method was in accordance with the requirement of the European Pharmacopoeia 2.9.19.
  • the above pharmaceutical compositions are stable in the relevant conditions and containers for enabling the administration of an appropriate dose of Compound A over a reasonable timescale.
  • EXAMPLE 7 Efficacy of Compound A formulated in a HP-B-cvclodextrin in RS4;11 xenograft model in mice using a once a week intravenous administration schedule
  • mice were subcutaneously injected into female SCID mice, provided by Charles River. When tumors reached the appropriate tumor volume, mice were randomized using Easy stat software. Compound A (15 mg/kg or 40 mg/kg expressed as free base) was injected i.v. once a week over two weeks.
  • a 20% w/v CavitronTM W7H5 solution containing a dose of 4 mg/mL of Compound A was prepared following this procedure.
  • a second solution containing a dose of 1.5 mg/mL of Compound A was also prepared by diluting further the previous solution with the 20% w/v CavitronTM W7H5 solution.
  • Tumor volume was estimated by measuring the minimum and maximum tumor diameters using the formula: (minimum diameter) (maximum diameter)/2. The last day with all control animals still present in the study, tumor growth inhibition was calculated using the formula:
  • TV means‘Tumor Volume’.
  • mice were sacrificed at the first measurement for which tumor volume exceeded 2000 mm or animal health deterioration. All experiments were conducted in accordance with the French regulations in force in 2018. SCID mice were maintained according to institutional guidelines.
  • Compound A formulated in a 20 % HR-b-cyclodextrin solution and administrated intravenously once a week for 2 weeks was shown to have antitumor activity at 15 mg/kg and 40 mg/kg on RS4;l l grafted female SCID mice ( Figure 1).
  • tumor growth inhibitions were 57.83% at 15 mg/kg and 75.52% at 40 mg/kg, with an exposure of 20463 ng.h/ml and 46509 ng.h/ml respectively.
  • the C max increased dose proportionally from 14692 ng/ml to 23290 ng/ml (Table 1).
  • Table 1 PK parameters measured for RS4;l l grafted female SCID mice after one i.v. treatment of‘Compound A, FT SOT formulated in a 20 % HR-b-cyclodextrin solution at 15 mg/kg and 40 mg/kg .
  • AUC t corresponds to the area under the observed blood concentration versus time curve from the time of administration to the last point.
  • phase I open label, non-randomised, non-comparative, multi-center study, was set up to evaluate Compound A intravenously administered, in patients with Relapse or Refractory Acute Myeloid Leukaemia, Non Hodgkin Lymphoma or Multiple Myeloma. Approximately 60 patients will be enrolled in the study. This study is designed in two parts: part one for dose escalation, part two for dose expansion. Primary objectives:
  • PK pharmacokinetic
  • Compound A will be administered via i.v. infusion via a central or peripheral venous line.
  • BHM Bayesian Hierarchical Model
  • EWOC overdose control
  • an adaptative Bayesian Logistic Regression Model (BLRM) guided by an escalation with overdose control (EWOC) method, will be used to make dose recommendations based on the occurrence of DLT(s) during Cycle 1 and estimate the MTD(s)/RP2D(s) for the Compound A administered as a single agent.
  • Treatment period :
  • the planned duration of treatment is until disease progression. Patients may be discontinued from treatment with the study drug earlier due to unacceptable toxicity and/or treatment is discontinued at the discretion of the investigator or the patient.
  • the objective of this study is to define the pH of precipitation of Compound A (hydrogen sulfate salt) from HR-b-cyclodextrin solution to better understand the risk of precipitation and select the pH of the drug product.

Abstract

The invention relates to a pharmaceutical composition comprising 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide, referred to herein as 'Compound A', or a pharmaceutically acceptable salt thereof, and a cyclodextrin. More specifically, the invention relates to a solid pharmaceutical composition comprising Compound A and a cyclodextrin, and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. Furthermore, the invention relates to the use of such compositions for the treatment of cancer.

Description

CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR
BACKGROUND OF THE INVENTION
The invention relates to a pharmaceutical composition comprising 5-(5-chloro-2-{ [(3.S')-3- Onorphol i n-4-yl methyl )-3,4-dihydroisoquinolin-2( 1 //)-yl]carbonyl } phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 //-pyrrole-3- carboxamide, referred to herein as‘Compound A’, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. More specifically, the invention relates to a solid pharmaceutical composition comprising Compound A and a cyclodextrin, and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. Furthermore, the invention relates to the use of such compositions for the treatment of cancer.‘Compound A’ as used herein optionally includes the pharmaceutically acceptable salts thereof.
The structure of Compound A is:
Figure imgf000002_0001
5-(5-chloro-2-{ [(3.S,)-3-(morpholin-4-ylmethyl)-3,4-dihydiOisoquinolin-2( 1 //)-yl]carbonyl } phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 H- pyrrole-3-carboxamide.
The preparation of Compound A, its use as a Bcl-2 inhibitor for the treatment of cancer and pharmaceutical formulations thereof, are described in WO 2015/011400, the content of which is incorporated by reference. The preparation is specifically disclosed in Example 386 of WO 2015/011400 in the form of a hydrochloride salt.
Compound A has limited aqueous solubility across all pHs (< 0.01 mg/mL for the free base and 1.4 mg/mL for‘Compound A, H2S04 at pH=2.5), including physiologically relevant pHs. In order to enable safe and effective administration of Compound A, and to elicit the required therapeutic effects, Compound A needs to be solubilized at higher concentration than its aqueous solubility.
There are different ways to solubilize poorly soluble compounds for parenteral administration. Typical approaches are the optimization of the pH or the use of co-solvents (e.g. PEG300, PEG400, propylene glycol, or ethanol). If these approaches are, for any reason, not feasible, the use of surfactants may be considered (e.g. Tween® 80 or Kolliphor™ ELP). However, these types of surfactants are frequently associated with adverse effects and not always able to solubilize the compounds of interest at targeted concentrations. Cyclodextrins are established as safe solubilizing agents, yet with limitations as they are not effective solubilizers for all compounds.
The aim of the current invention is to provide a composition which can conveniently be used to solubilize and parenterally deliver Compound A at targeted concentrations for having clinical efficacy. In particular, there is a need to provide a pharmaceutical composition for Compound A which is safe and efficacious. Further aims are to provide a composition which is stable in the relevant conditions and containers, and which enables administration of an appropriate dose of Compound A over a reasonable timescale. In a further aim, the composition should be able to be manufactured by a reliable and robust process for the preparation of parenteral dosage forms.
SUMMARY The present invention provides a composition comprising Compound A and a cyclodextrin, suitable for parenteral administration to patients. In particular, such administration is by intravenous injection or infusion. The invention further provides a solid cyclodextrin-based composition which can be dissolved in one or more solvents shortly before administration to the patient, in order to provide the composition suitable for parenteral administration. Preferably, the solid cyclodextrin-based composition according to the invention is placed in an aqueous solution. In the pharmaceutical composition thus prepared, Compound A is solubilized by means of a cyclodextrin.
Preferably, the invention provides a composition comprising Compound A which has an optimal physical stability; for example the precipitation of components is avoided when the solid composition is placed in an aqueous solution and further diluted in a glucose solution and when the resulting pharmaceutical composition is injected in the plasma. Preferably, the invention provides a pharmaceutical cyclodextrin-based composition comprising Compound A, which is chemically and physically stable. At high cyclodextrin concentration, it is well known that drug/cyclodextrin complexes have tendency to form large and visible particles (Saokham el al, Molecules 2018 23 page 1161). These solid microparticles obviously prevent a sterile filtration operation. Interestingly, the drug/cyclodextrin solutions according to the invention remain perfectly clear and can be very easily filtrated on 0.2 pm filter.
Preferably, the invention provides a solid pharmaceutical composition having an acceptable reconstitution time in solvents for injection (more preferably in water for injection), and thus allowing ease of use for the preparation of the pharmaceutical composition that will be parenterally delivered.
Preferably, the invention provides a pharmaceutical cyclodextrin-based composition which enables a fast solubilisation and a good distribution of Compound A after intravenous administration.
Overall, the invention described herein enables effective administration of Compound A to patients, despite the challenging physico-chemical characteristics of Compound A. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the efficacy of Compound A in a cyclodextrin-based formulation after 15 and 40 mg/kg administrated i.v. once a week over two weeks in RS4;l l grafted female SCID mice. Figure 2 shows the tolerability of Compound A in a cyclodextrin-based formulation after 15 and 40 mg/kg administrated i.v. once a week over two weeks in RS4;l l grafted female SCID mice. Body weight loss is measured versus time after treatment.
DETAILED DESCRIPTION OF THE INVENTION
‘Compound A’ means 5-(5-chloro-2-{ [(3.S')-3-(morphol in-4-yl methyl )-3, 4- dihydroisoquinolin-2(l )-yl]carbonyl} phenyl)-/V-(5-cyano-l, 2-dimethyl- l -pyrrol-3-yl)- /V-(4-hydroxyphenyl)- 1 ,2-dimethyl- l -pyrrole-3-carboxamide.
‘Compound A, H2S04’ means that 5-(5-chloro-2-{ [(3.S')-3-(morphol in-4-yl methyl )-3, 4- dihydroisoquinolin-2(l )-yl]carbonyl} phenyl)-/V-(5-cyano- 1 ,2-dimethyl- 1 /-pyriol -3-yl )- V-(4-hydroxyphenyl)-l, 2-dimethyl- l -pyrrole-3-carboxamide is in the form of a hydrogen sulfate salt.
‘Free molecule’ and‘free base’ are used interchangeably herein and refer to Compound A when not in salt form.
The cyclodextrin described herein is a natural or derived cyclodextrin. Natural cyclodextrins comprise three well-known industrially produced (major and minor) cyclic oligosaccharides. The most common natural cyclodextrins are a, b, and g consisting of 6, 7, and 8 glucopyranose units. Derived cyclodextrins include hydroxyalkylated cyclodextrins selected from the group consisting of hydroxyethyl cyclodextrin, hydroxypropyl cyclodextrin and hydroxybutyl cyclodextrin. In a particular embodiment, the cyclodextrin is the b-cyclodextrin itself or its derivatives. The derivatives herein mean b-cyclodextrins having various substituents, including methyl- b-cyclodextrin, ethyl^-cyclodextrin, (2- hydroxypropyl)-P-cyclodextrin, (3-hydroxypropyl)-P-cyclodextrin, (2-hydroxyethyl)-P- cyclodextrin, carboxymethyl-P-cyclodextrin, carboxymethyl-ethyl-P-cyclodextrin, diethyl- b-cyclodextrin, dimethyl- b-cyclodextrin, trimethyl-P-cyclodextrin, glucosyl-b- cyclodextrin, hydroxybutenyl-P-cyclodextrin, maltosyl-P-cyclodextrin, randomly methylated-P-cyclodextrin, sulfobutylether-P-cyclodextrin, 2- selenium-bridged b- cyclodextrin, and 2-tellurium-bridged b-cyclodextrin. Besides b-cyclodextrin, 2- hydroxypropyl-Y-cyclodextrin can be used in the present invention. Derived cyclodextrins also include polymerized cyclodextrins, which are high molecular weight compounds, either water-soluble or insoluble. The examples of polymerized cyclodextrins are soluble anionic //-cyclodextrin polymer, soluble y-cyclodextrin polymer, and epichlorohydrin b- cyclodextrin polymer.
‘a-cyclodextrin’,‘b-cyclodextrin’ and‘y-cyclodextrin’ are also named‘alfadex’,‘betadex’, and‘gammadex’, respectively.
ΉR- b-cyclodextrm’ is also named‘hydroxypropyl- b-cyclodextrin’ or‘2-hydroxypropyl- b-cyclodextrin’ or ‘hydroxypropylbetadex’. In particular, the HP- b-cyclodextrin is marketed with the following product names: Cavitron™ W7HP7 (typical degree of substitution: 6.0-8.0 ; approximate molecular weight: 1520), Cavitron™ W7HP5 (typical degree of substitution: 4.1-5.1 ; approximate molecular weight: 1410), Kleptose™ HPB or Kleptose™ HP. ‘SBE- b-cyclodextrin’ is also named‘sodium sulfobutylether- b-cyclodextrm’ or‘betadex sulfobutyl ether sodium’. In particular, the SBE- b-cyclodextrin is marketed with the following product names: Dexsolve™ or Captisol™.
The pharmaceutical composition described herein is, in particular, a pharmaceutical cyclodextrin-based composition. A ‘pharmaceutical cyclodextrin-based composition’ means a composition comprising a cyclodextrin, which is suitable for pharmaceutical administration. ‘TPGS’ means d-a-tocopheryl polyethylene glycol succinate or tocopher solan. It is a water-soluble form of vitamin E (a- tocopherol).
‘Tonicity adjusting agent’ means a pharmaceutically acceptable compound which can be added to a formulation to make it isotonic with human plasma. Tonicity adjusting agents include for example dextrose, glucose, mannitol, sucrose, lactose, trehalose, glycerine and NaCl, in particular sucrose or glycerine, more particularly sucrose. Tonicity is the ‘effective osmolality’ and is equal to the sum of the concentrations of the solutes which have the capacity to exert an osmotic force across the membrane. Parenteral formulations should be isotonic with blood plasma. Tonicity adjusting agents are well known to the skilled person.
A‘buffer’ is used to prevent changes in the pH of a solution, and suitable examples are well-known to the skilled formulator.
‘Container’ means an ampoule or vial with rubber stopper and cap, single or double chamber syringe, infusion bag or bottle made from polymeric materials or glass, suitable for housing compositions for parenteral administration. It also includes any vessel for holding liquids.
As used herein, the term “solvent” is a solvent used for the reconstitution of a pharmaceutical composition suitable for parenteral administration, starting from a solid pharmaceutical composition. The solid pharmaceutical composition is preferably a lyophilisate. In a preferred mode, the solvent is water. In the context of the invention, the water used is water for injection.
As used herein, the term‘comprising’ means‘including’, and is not intended to exclude the presence of any additional component, unless the context suggests otherwise, for example when the components together sum to 100 %. As used herein, the term‘treat’,‘treating’ or‘treatment’ of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder ( i.e ., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, ‘treat’, ‘treating’ or ‘treatment’ refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, ‘treat’, ‘treating’ or ‘treatment’ refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
As used therein, a “therapeutically effective amount of the composition” means an effective amount of the composition according to the invention containing an effective dose of active principle to elicit a therapeutic benefit for the patient. The dose of Compound A administered according to the invention is from 5 mg to 1000 mg (expressed as free base).
Mixing ‘shortly before administration to patient’ means up to three days before, in particular up to 24 hours before, and for example up to 6 hours before administration to the patient. Embodiments
Described below are a number of embodiments of the invention.
El. A solid pharmaceutical composition comprising Compound A which is 5-(5- chloro-2-{ [(35,)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(l /)-yl]carbonyl} phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 H- pyrrole-3-carboxamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
E2. A solid pharmaceutical composition according to El, wherein Compound A is in the form of the hydrochloride salt.
E3. A solid pharmaceutical composition according to El, wherein Compound A is in the form of a hydrogen sulfate salt. E4. A solid pharmaceutical composition according to any of embodiments El to E3, wherein the cyclodextrin is a sodium sulfobutylether-P-cyclodextrine (SBE- b- cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin).
E5. A solid pharmaceutical composition according to E4, wherein the sulfobutylether- b-cyclodextrin is selected from Dexsolve™ and Captisol™.
E6. A solid pharmaceutical composition according to El to E3, wherein the cyclodextrin is a HP- b-cyclodextrin, more particularly Cavitron™ W7HP7, Cavitron™ W7HP5, Kleptose™ HPB or Kleptose™ HP.
E7. A solid pharmaceutical composition according to E6, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is at least 5 : 1. In another embodiment, the weight/weight ratio between the HP- b-cyclodextrin and Compound A is at least 10 : 1 for the solid pharmaceutical compositions according to the invention.
E8. A solid pharmaceutical composition according to E7, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is 5 : 1. In another embodiment, the weight/weight ratio between the HP- b-cyclodextrin and Compound A is 10 : 1 for the solid pharmaceutical compositions according to the invention.
E9. A solid pharmaceutical composition according to any of embodiments E6 to E8, wherein the HP- b-cyclodextrin is Cavitron™ W7HP5.
E10. A solid pharmaceutical composition according to any of embodiments E6 to E8, wherein the HP- b-cyclodextrin is Kleptose™ HPB.
El l. A solid pharmaceutical composition according to any of embodiments El to E10, further comprising one or more pharmaceutically acceptable excipients. In another embodiment, the pharmaceutically acceptable excipient is a surfactant. E12. A solid pharmaceutical composition according to any of embodiments El to E10, comprising at least one pharmaceutically acceptable excipients selected from glucose, mannitol, sucrose, trehalose and sorbitol.
E13. A solid pharmaceutical composition according to any of embodiments El to E12, which is a lyophilisate.
E14. A pharmaceutical composition comprising Compound A which is 5-(5-chloro-2- { [(35,)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(l//)-yl]carbonyl}phenyl)-/V-(5- cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 //-pyrrole-3- carboxamide, or a pharmaceutically acceptable salt thereof, a cyclodextrin and one or more solvents. In another embodiment, the pharmaceutical composition further comprises a surfactant.
E15. The pharmaceutical composition according to E14 wherein the solvent is an aqueous buffer or water, and more particularly water.
E16. The pharmaceutical composition according to E14 or E15, wherein Compound A is in the form of the hydrochloride salt.
E17. The pharmaceutical composition according to E14 or E15, wherein Compound A is in the form of a hydrogen sulfate salt.
E18. The pharmaceutical composition according to E17, having a pH value comprised between 2.8 and 3.2, more particularly the pH value is comprised between 2.9 and 3.1. E19. The pharmaceutical composition according to E17 having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5.
E20. The pharmaceutical composition according to any of embodiments E14 to E19, wherein the cyclodextrin is a sodium sulfobutylether-P-cyclodextrin (SBE- b-cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin). E21. The pharmaceutical composition according to E20, wherein the sulfobutylether-b- cyclodextrin is selected from Dexsolve™ and Captisol™.
E22. The pharmaceutical composition according to any of embodiments E14 to E19, wherein the cyclodextrin is a HP- b-cyclodextrin, more particularly Cavitron™ W7HP7, Cavitron™ W7HP5, Kleptose™ HPB or Kleptose™ HP.
E23. The pharmaceutical composition according to E22, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is at least 5 : 1. In another embodiment, the weight/weight ratio between the HP- b-cyclodextrin and Compound A is at least 10 : 1 for the pharmaceutical compositions according to the invention. E24. The pharmaceutical composition according to E23, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is 5 : 1. In another embodiment, the weight/weight ratio between HP- b-cyclodextrin and Compound A is 10 : 1 for the pharmaceutical compositions according to the invention.
E25. The pharmaceutical composition according to any of embodiments E22 to E24, wherein the HP- b-cyclodextrin is Cavitron™ W7HP5.
E26. The pharmaceutical composition according to any of embodiments E22 to E24, wherein the HP- b-cyclodextrin is Kleptose™ HPB.
E27. The pharmaceutical composition according to any of embodiments E22 to E26 having a concentration comprised between 50 and 300 mg/mL of HP- b-cyclodextrin. E28. The pharmaceutical composition according to E27 having a concentration of 200 mg/mL of HP- b-cyclodextrin.
E29. The pharmaceutical composition according to any of embodiments E22 to E26 having a concentration of 20 mg/mL of Compound A, free base. E30. The pharmaceutical composition according to any of embodiments E14 to E29, further comprising a tonicity adjusting agent.
E31. The pharmaceutical composition according to E30, wherein the tonicity adjusting agent is selected from glucose, mannitol, sucrose, trehalose and sorbitol. E32. The pharmaceutical composition according to E14 comprising ‘Compound A,
H2S04’and Cavitron™ W7HP5, and having a pH value comprised between 2.8 and 3.2, more particularly the pH value is comprised between 2.9 and 3.1. In another embodiment, the pharmaceutical composition further comprises water.
E33. The pharmaceutical composition according to E14 comprising ‘Compound A, H2S04’ and Cavitron™ W7HP5, and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5. In another embodiment, the solvent used in the pharmaceutical composition is water.
E34. The pharmaceutical composition according to E14:
comprising‘Compound A, H2S04’, Cavitron™ W7HP5 and water, and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5,
wherein the molar ratio between Cavitron™ W7HP5 and Compound A (free base) is at least 5 : 1.
E35. The pharmaceutical composition according to E14:
- comprising‘Compound A, H2S04’, Cavitron™ W7HP5 and water,
and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5,
wherein the molar ratio between Cavitron™ W7HP5 and Compound A (free base) is 5 : 1. E36. The pharmaceutical composition according to E14: comprising‘Compound A, H2S04’, Cavitron™ W7HP5 and water,
and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5,
wherein the weight/weight ratio between Cavitron™ W7HP5 and Compound A (free base) is at least 10 : 1.
E37. The pharmaceutical composition according to E14:
comprising‘Compound A, H2S04’, Cavitron™ W7HP5 and water, and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5,
- wherein the weight/weight ratio between Cavitron™ W7HP5 and Compound A
(free base) is 10 : 1.
E38. The pharmaceutical composition according to E14 comprising ‘Compound A, H2S(V, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4. E39. The pharmaceutical composition according to E14:
comprising‘Compound A, H2S04’, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4,
wherein the molar ratio between Cavitron™ W7HP5 and Compound A (free base) is at least 5 : 1.
E40. The pharmaceutical composition according to E14:
comprising‘Compound A, H2S04’, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4,
wherein the molar ratio between Cavitron™ W7HP5 and Compound A (free base) is 5 : 1.
E41. The pharmaceutical composition according to E14: comprising‘Compound A, H2S04’, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4,
wherein the weight/weight ratio between Cavitron™ W7HP5 and Compound A (free base) is at least 10 : 1.
E42. The pharmaceutical composition according to E14:
comprising‘Compound A, EESCV, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4,
wherein the weight/weight ratio between Cavitron™ W7HP5 and Compound A (free base) is 10 : 1.
E43. The pharmaceutical composition according to any of embodiments E14 to E42, for parenteral administration.
E44. The pharmaceutical composition according to E43, for infusion or intravenous injection.
E45. A process for preparing a pharmaceutical composition according to E14 suitable for parenteral administration comprising the dissolution of a solid pharmaceutical composition as defined in El to El 3 in a solvent, more particularly in water.
E46. A process according to E45 comprising an additional step of dilution with an infusion solution, more particularly with a solution of 5% Glucose.
E47. A process according to E45 or E46, wherein the dissolution takes place immediately prior to administration to the patient.
E48. A method of modulating Bcl-2 receptor activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the composition according to any of embodiments E14 to E44. E49. A method of treating cancer, comprising administering to the subject a therapeutically effective amount of the composition according to any of embodiments E14 to E44.
E50. A method according to E49, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
E51. A method according to E50, wherein the cancer is selected from non-Hodgkin's B- cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, more particularly non-Hodgkin's B-cell lymphoma, multiple myeloma and acute myeloid leukaemia. E52. A method according to any of embodiments E48 to E51, wherein the composition according to any of embodiments E14 to E36, is administered once weekly.
E53. The pharmaceutical composition according to any of embodiments E14 to E44 for use as a medicament.
E54. A pharmaceutical composition for use according to E53, wherein said use is in the treatment of cancer, in particular wherein cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the cesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. E55. A pharmaceutical composition for use according to embodiment E54, wherein said cancer is selected from non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, more particularly non-Hodgkin's B-cell lymphoma, multiple myeloma and acute myeloid leukaemia.
E56. Use of solid pharmaceutical composition according to any of El to E13, for the preparation of a medicament to treat cancer.
E57. The use according to E56, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer, in particular non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia, and more particularly non-Hodgkin's B-cell lymphoma, multiple myeloma and acute myeloid leukaemia.
E58. A combination comprising:
· a pharmaceutical composition according to any of embodiments E14 to E44, and
• one or more therapeutically active agents, for simultaneous, sequential or separate use.
Advantageously, in a particular embodiment of the invention, there is provided a lyophilisate comprising Compound A and Cavitron™ W7HP5, which can be dissolved in a solvent, preferably water, shortly before administration to produce a transparent composition. In another embodiment, the previous solution can be further diluted with a solution of Glucose 5%. In particular, this is achieved by transferring the pharmaceutical composition comprising Compound A and Cavitron™ W7HP5 as described herein into a 250 mL glucose bag.
The preparation of the solid pharmaceutical composition according to the invention may comprises a step of adjustment of the pH of the initial solution before drying. In particular, the pH of the solution is adjusted by adding drop by drop, either a HC1 solution or a NaOH solution, depending on the concentration of Compound A contained in the initial solution.
EXAMPLE 1: Solubility studies of Compound A in various carriers for the preparation of a formulation suitable for the parenteral route
The objective of these studies is to define the solubility at saturation of Compound A with the aim of formulating an injectable solution characterised by a concentration of active ingredient which is sufficiently high to meet the therapeutic needs of an administration in humans. In particular, it is necessary to have available a carrier which allows high daily administrable doses of active ingredient to be achieved, considering the permitted daily exposures for the carrier itself. In particular, the permitted daily exposure for the HR-b- cyclodextrin amounts to 320 mg/kg/day.
The solubility of‘Compound A, H2S04 was studied in various media, including:
citrate buffer (pH = 2; 50 mM), acetate buffer (pH = 4; 50 mM) and phosphate buffer (pH = 6-7.4; 67.7 mM);
- cyclodextrins of the type sulfobutyl ether b-cyclodextrin (SBE^-cyclodextrin) or hydroxypropyl b -cyclodextrin (HR-b-cyclodextrin); more precisely, the SBE-b- cyclodextrin tested is Dexsolve™ marketed by Cyclolab, while the HR-b- cyclodextrins tested are Cavitron™ W7HP7 and Cavitron™ W7HP5 marketed by Wacker; Kleptose™ HP and Kleptose™ HPB marketed by Roquette;
- surfactants such as polysorbate 80 and Kolliphor™ ELP;
the mixture PEG400/ethanol/0.9% NaCl (40/10/50). Preparation of the media containing the various carriers to be tested:
(i) 20% by weight cyclodextrin solution
5 g of the cyclodextrin studied (Dexsolve™, Cavitron™ W7HP7, Cavitron™ W7HP5, Kleptose™ HP or Kleptose™ HPB) are weighed into a 20 mL graduated flask. Approximately 15 mL of water are added and the whole obtained is subjected to magnetic stirring. The volume is then made up to 25 mL by the addition of water. The whole is placed under magnetic stirring for 10 minutes.
(ii) 2% by weight surfactant solutions
1 g of the surfactant studied is weighed into a 50 mL graduated flask. The volume is then made up to 50 mL by means of 0.9% NaCl solution. The whole is placed under magnetic stirring for 1 hour.
(iii) PEG/ethanol/0.9% NaCl solution (40/10/50) v/v/v
20 mL of PEG 400, 5 mL of ethanol and 25 mL of NaCl are taken. The whole is placed in a 100 mL Erlenmeyer flask and stirred magnetically for 30 minutes. Solubility test:
Approximately 340 mg of‘Compound A, H2S04’ are weighed into a 5 mL tube. 3 mL of the medium containing the carrier to be tested are then added. The whole is then placed under magnetic stirring for 2 hours or 24 hours. The suspension or solution so obtained is passed through a 0.2 pm filter (PVDL membrane - Millipore) before being analysed by HPLC. In addition, the presence of degradation products of Compound A was investigated in the samples stored for 72 hours at ambient temperature. Results:
Figure imgf000019_0001
Conclusion:
The 5 carriers permitting substantial solubilisation of Compound A are: Cavitron™ W7HP5 ~ Kleptose™ HPB > Kleptose™ HP ~ Dexsolve™ ~ Cavitron™ W7HP7 > PEG400 > PEG400/EtOH/0.9% NaCl (40/10/50).
The solubilities in those media are between 10 and 30 mg/mL after 24 hours' stirring. Cavitron™ W7HP5 and Kleptose™ HPB are the most effective carrier for solubilising Compound A and permitting the manufacture of solutions with a sufficient content of active ingredient for the purpose of parenteral administration in humans. In particular, the solutions wherein the molar ratio between the HR-b-cyclodextrin and Compound A is 5 : 1 are a compromise between drug loading and content of HR-b-cyclodextrin in accordance with the permitted daily exposure. Higher ratios are also acceptable within the limit of the permitted daily exposure.
The solubilities obtained after 2 hours' stirring were of the same order of magnitude. No significant quantity (> 0.1%) of degradation product or by-product was measured in the samples. EXAMPLE 2: Solubility studies of Compound A in a HP-B-cvclodextrin as a function of the pH
Study 1 starting from Compound A, HC1
The solubility of Compound A, HC1 was studied in the presence of a HR-b-cyclodextrin as a function of the pH by means of various buffers (acetate pH = 4 and phosphate pH = 7.4).
Preparation of the media containing the various carriers to be tested:
(i) Acetate buffer pH 4
0.75 g of sodium acetate trihydrate (NaC2H302, 3H20) is introduced into a 250 mL graduated flask. 3.5 mL of 2 N acetic acid solution (produced from glacial acetic acid) are added. The volume is then made up to 250 mL by means of 0.9% NaCl solution, and the whole is then stirred. The pH is then adjusted to 4 by means of 1 N HC1 solution.
(ii) Phosphate buffer pH 7.4
2.075 g of monobasic potassium phosphate (KH2P04) and 0.238 g of dibasic sodium phosphate (Na2HP04) are dissolved in 100 mL of water. The whole is stirred until solubilisation is complete. The volume is then made up to 250 mL by means of 0.9% NaCl solution. The pH is adjusted to the desired value (7.4) by means of 1N sodium hydroxide solution.
(iii) 20% by weight cyclodextrin solution
2 g of the cyclodextrin studied (Cavitron™ W7HP5) are weighed into a 10 mL graduated flask. The volume is then made up to 10 mL by means of a water/0.9% NaCl mixture (80/20) or an acetate or phosphate buffer solution, depending on the desired pH.
Test of maximum solubility:
Approximately 10 mg of Compound A, HC1 are weighed. 1 mL of the medium containing the carrier to be tested, that is to say Cavitron™ W7HP5 without pH adjustment, Cavitron™ W7HP5 adjusted to pH = 4 or Cavitron™ W7HP5 adjusted to pH = 7.4, is then added. The whole is then placed under magnetic stirring. Then, 5 mg of Compound A, HC1 are added. The operation is repeated if the compound solubilises. The mixture is stirred for 24 hours. The suspension so obtained is passed through a 0.45 pm filter before being analysed by HPLC chromatography.
Results:
Figure imgf000021_0001
Study 2 starting from Compound A, H7SO4
The solubility of ‘Compound A, H2S04’ was studied in the presence of a HR-b- cyclodextrin as a function of the pH.
Preparation of the 20% m/v cyclodextrin solution (200 mg/mL)
10 g of the cyclodextrin studied (Cavitron™ W7HP5) are placed in a 50 mL graduated flask. 40 mL of water are then added. The whole is placed under magnetic stirring. The volume is then made up with water to 50 mL.
Solubility test:
Approximately 856.7 mg of ‘Compound A, H2S04’ are weighed. 30 mL of the medium containing the carrier to be tested, that is to say Cavitron™ W7HP5, are then added. The whole is placed under magnetic stirring for 24 hours. The suspension so obtained is passed through a 0.2 pm filter (PALL - PES membrane - diameter 25 mm) before being analysed by HPLC.
In other tests, the pH of the solution is then modified by means of 0.1 N NaOH solution until values of 4 and 8.8 are reached, before the analysis by HPLC chromatography is carried out. Results:
Figure imgf000022_0001
A precipitate is visually observed from pH 3.2.
Conclusion:
These results confirm that Compound A is solubilised effectively by Cavitron™ W7HP5. The solubility is significantly dependent on the pH of the solution. For‘Compound A, H2S04’, precipitation is observed from pH 3.2 and becomes more marked when the pH increases. This critical pH value depends on process parameters. Further experiments were carried out with optimized complexation and dissolution processes to define precisely the pH value for which precipitation occurs. This study is detailed in the Example 9. EXAMPLE 3: Study of the phenomena of precipitation of Compound A formulated in various carriers when diluted in canine plasma
The objective of this study is to evaluate the possible precipitation of Compound A formulated in a HR-b-cyclodextrin (i.e. Cavitron™ W7HP5) or in a PEG400/EtOH/0.9% NaCl mixture (in the presence or absence of TPGS) in canine plasma.
The following 7 formulations were tested:
- 3 mg/mL of Compound A in a 200 mg/mL Cavitron™ W7HP5 solution in a water/0.9% NaCl mixture (70/30),
- 6 mg/mL of Compound A in a 200 mg/mL Cavitron™ W7HP5 solution in a water/0.9% NaCl mixture (70/30), - 3 mg/mL of Compound A in a medium obtained by dilution in a glucose 5% solution for infusion (G5 solution) of a solution containing a dose of 20 mg/mL of Compound A in a 200 mg/mL Cavitron™ W7HP5 solution in a water/NaCl mixture (70/30),
- 3 mg/mL of Compound A in a PEG 400/EtOH/0.9% NaCl mixture (40/10/50),
- 6 mg/mL of Compound A in a PEG 400/EtOH/0.9% NaCl mixture (40/10/50),
- 3 mg/mL of Compound A in a PEG 400/EtOH/0.9% NaCl/TPGS mixture (40/10/49.5/0.5),
- 6 mg/mL of Compound A in a PEG 400/EtOH/0.9% NaCl/TPGS mixture (40/10/49.5/0.5). Two protocols of addition of the formulations to the plasma were tested:
- 10 pL/min for 15 minutes at 37°C,
- 7.5 pL/min for 10 minutes at 37°C.
Preparation of the media containing the various carriers to be tested:
(i) 200 mg/mL cyclodextrins
Weigh 4 g of Cavitron™ W7HP5 into a 20 mL graduated flask. Add approximately 15 mL of water /0.9% NaCl mixture (70/30) v/v. The whole is placed under magnetic stirring until the components have dissolved completely. Make up the volume of the medium to 20 mL by adding the necessary quantity of water/0.9% NaCl and stir the whole magnetically for 10 minutes. (ii) PEG400/EtOH/0.9% NaCl solution
Take 8 mL of PEG 400, 2 mL of ethanol and 10 mL of 0.9% NaCl. Introduce them into a 25 mL Erlenmeyer flask and place the whole under magnetic stirring for 1 hour.
(iii) PEG/EtOH/0.9 % NaCl/TPGS solution
Take 8 mL of PEG 400, 2 mL of ethanol and 9.9 mL of 0.9% NaCl. Introduce them into a 25 mL Erlenmeyer flask and place the whole under magnetic stirring for 1 hour. Weigh
100 mg of TPGS and add it to the preceding mixture. Stir magnetically for 16 hours. (iv) Preparation of the mixtures for the solubility test
Weigh the desired quantity of‘Compound A, H2S04’ (X mg). Add 5 mL of the medium to be tested (Cavitron™ W7HP5, PEG/EtOH/O.9% NaCl solution, PEG/EtOH/O.9% NaCl/TPGS solution). Place the medium so obtained under magnetic stirring at ambient temperature for 24 hours. It should be noted that, in order to prepare the 20 mg/mL solution of Compound A in cyclodextrin, it is necessary to heat the medium at 60°C for 2 hours. In the case of the solutions based on cyclodextrin, adjust the pH to 3. Pass the solutions so obtained through a 0.2 pm filter (PVDF membrane - Millipore).
Figure imgf000024_0001
For the solution prepared at 20 mg/mL, then perform dilution in G5 solution in order to obtain the final concentration of 3 mg/mL.
Dissolution in the plasma & Results
Place 1.0 mL of plasma in a vial of suitable volume. Place the vial in an oven set at 37 °C. Then:
add at 10 pL/min each solution to be tested for 15 minutes,
or
add at 7.5 pL/min each solution to be tested for 10 minutes.
Stir manually after adding the solution, then allow the mixture to stand.
Pass the solutions so obtained through a 0.2 pm filter (PVDF membrane - millipore).
For the 7 formulations tested, the pH measured after dilution in the plasma was between 7.5 and 8.
Figure imgf000025_0001
Whatever the protocol of addition applied, precipitation is observed for all the following samples:
- PEG/EtOH/0.9 % NaCl 3 and 6 mg/mL
- PEG/EtOH/0.9 % NaCl/TPGS 3 and 6 mg/mL
This precipitation is immediate in the samples without TPGS and appears slightly later for those containing TPGS.
Precipitation is observed from 8 minutes with the protocol of addition at 10 pL/min for 15 minutes with the solution of Cavitron™ W7HP5 containing a dose of 6 mg/mL of active ingredient. No precipitation is observed visually for the other tests in which Compound A is formulated in Cavitron™ W7HP5.
EXAMPLE 4: Study of the physical stability of lvophilisates made from Compound A 5 and a HP-B-cvclodextrin in the presence or absence of other excipients
Preparation of 20% cyclodextrin solutions containing a dose of 20 mg/mL of Compound A, in the absence or in the presence of glucose
In a 100 mL flask, introduce 20 g of Cavitron™ W7HP5 and 2.26 g of ‘Compound A, H2S04’. Heat the whole at 60°C under vigorous magnetic stirring until solubilisation of the f 0 components of the mixture is complete. Allow to return to ambient temperature, transfer to a beaker and then measure the pH. Adjust the pH to 3 with 0.5 N NaOH solution. Where applicable, add 1.2 g of anhydrous glucose.
Make up the volume with water to 100 mL. Then check the pH and the osmolality. Filter the solution obtained through a cellulose syringe filter. The solutions so obtained (with or 15 without glucose) are then lyophilised.
Preparation of 20 % cyclodextrin solutions containing a dose of 15 mg/mL of Compound
A, in the absence or in the presence of different sugars including glucose, mannitol, sucrose, trehalose and sorbitol
In a 100 mL flask, introduce 20 g of Cavitron™ W7HP5 and 1.70 g of ‘Compound A, 20 HiSCV. Heat the whole at 60°C under vigorous magnetic stirring until solubilisation of the components of the mixture is complete. Allow to return to ambient temperature, transfer to a beaker and then measure the pH. Adjust the pH to 4.0 with 1.0 N NaOH solution. Where applicable, add 1.0 or 2.0 g of anhydrous glucose, mannitol, sucrose, trehalose or sorbitol. Make up the volume with water to 100 mL. Then check the pH and the osmolality. Filter 25 the solution obtained through a cellulose syringe filter. The solutions so obtained (with or without glucose) are then lyophilised.
Results
The osmolality of the solutions containing between 10 to 20 mg/mL of glucose, mannitol, sucrose, trehalose or sorbitol is greater than 400 mOsm/kg, while that of the solutions without glucose is approximately 300 mosm/kg. The fact of omitting the glucose from the formulation reduces the osmolality significantly. However, the osmolality of the solutions without glucose is acceptable for the purpose of parenteral administration.
The lyophilisates obtained, with and without glucose, mannitol, sucrose, trehalose or sorbitol, have robust physical properties, namely a good cake appearance and an acceptable reconstitution time.
Conclusions
This study shows that the presence of glucose, mannitol, sucrose, trehalose or sorbitol is not essential in the formulation of the lyophilisates, which allows the risks of degradation associated with this excipient to be overcome. Additional tests in the presence of 5% glucose or 5% mannitol in solutions containing a dose of 20 mg/mL of Compound A and 200 mg/mL of HR-b-cyclodextrin did not result in an improvement in the physical properties of the lyophilisates.
EXAMPLE 5: Preparation of lyophilisates of Compound A solubilised in a HP-B- cvclodextrin in 20 ml. vials
The lyophilisates are prepared in 20 mL vials in which it will be possible to reconstitute the solution to be administered by the parenteral route. They are obtained by lyophilisation of a 20% Cavitron™ W7HP5 solution containing a dose of 20 mg/mL of Compound A (free base). Procedure
In a 5 L reactor, weigh 1500 g of water. With magnetic stirring, create a vortex and then pour in 600 g of Cavitron™ W7HP5. Stir the medium at ambient temperature until the cyclodextrin is solubilised completely, and add 68.16 g of‘Compound A, H2S04’ and heat the solution to not more than 60 °C. Place the suspension under magnetic stirring for several hours and then allow the medium to return to a temperature below 30°C. Measure the pH of the solution so obtained, then adjust it to pH 3.0 with 0.5M NaOH solution poured slowly. Make up the solution to a volume of 3 L by adding water, while maintaining magnetic stirring.
Pass the solution so obtained through a 0.2 pm filter. Fill the 20 mL vials with the filtered solution so that each vial contain at least 150 mg of Compound A (expressed as free base) and subject the samples to a lyophilisation step.
The resulting lyophilisate is intended to be used for the preparation of a pharmaceutical composition for parenteral administration. Further experiments show that the pH of the pharmaceutical compositions dosed at 20 mg/mL of Compound A after reconstitution in water starting from the above lyophilisate is mostly identical to the pH of the solution observed before the lyophilisation step, i.e. comprised between 2.9 and 3.1. Consequently the pH specification of the drug product has been set up between 2.5 and 3.5.
EXAMPLE 6: Stability of the solutions of Compound A when diluted in 250 mL of glucose 5% solution
Figure imgf000028_0001
The aim of this study is to determine the pH for 7 different concentrations of Compound A solubilised in Cavitron™ W7H5 and diluted in a bag of 250 mL of glucose 5% (G5 solution), and then to check visually that there has been no precipitation at the different concentrations tested (12 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1 g of active ingredient in 250 mL of G5). The Compound A used is in the form of a hydrogen sulfate salt. Invisible particulate contamination of the solutions was also controlled by light obscuration technique.
Procedure
A mother solution containing a dose of 200 mg/mL of Cavitron™ W7H5 and 20 mg/mL of Compound A (expressed for the free base) is prepared by dissolving a lyophilisate as described in Example 5 in the necessary amount of water. The solution so obtained is then diluted by means of glucose 5% solution (G5).
The pH of the solutions obtained is measured and the appearance of the solutions is observed. The pH is increased using NaOH 0.01N solution until a precipitation is observed.
Results
The pH of G5 solution is between 3.02 and 4.353.
Figure imgf000029_0001
The solutions of Compound A solubilised by means of a Cavitron™ W7H5 solution do not precipitate when diluted in G5 solution for concentrations between 12 and 1000 mg/250 mL of G5 solution. Compound A as formulated in the present invention can therefore be reconstituted in water and diluted in a bag of 250 mL of glucose 5% over a wide range of concentrations before being administered by the parenteral route.
Moreover, studies of physical stability over time (24 h, 48 h and 72 h) are carried out on the solutions obtained hereinbefore. In particular, these studies include the particle count of the tested solutions in accordance with the method described in the text of the European Pharmacopoeia 2.9.19. Tests l.B (i.e. counting of the sub-visible particles by light obscuration).
Studies of chemical stability over time (24 h, 48 h and 72 h) are also put in place in order to ensure the stability of the product under laboratory light (1500 lux) and various heat conditions (ambient temperature, 5°C). These studies include especially measurements of the amount of active ingredient and degradation products. Pharmaceutical compositions of Compound A solubilised by means of a Cavitron™ W7H5 solution diluted in G5 solution were tested for the following concentrations: 12 mg/250 mL, 20 mg/250 mL and 1000 mg/250 mL of G5 solution. No significant chemical degradation product was observed in all the conditions tested during 72 h. Lurthermore, the rate of sub-visible particles detected using the light obscuration method was in accordance with the requirement of the European Pharmacopoeia 2.9.19. In conclusion, the above pharmaceutical compositions are stable in the relevant conditions and containers for enabling the administration of an appropriate dose of Compound A over a reasonable timescale.
EXAMPLE 7: Efficacy of Compound A formulated in a HP-B-cvclodextrin in RS4;11 xenograft model in mice using a once a week intravenous administration schedule
The in vivo therapeutic effect of Compound A formulated in a solution comprising 20 % of a HR-b-cyclodextrin w/v, was determined in the RS4;l l model after intravenous administration.
Material and method
RS4;l l cell line, obtained from ATCC, were subcutaneously injected into female SCID mice, provided by Charles River. When tumors reached the appropriate tumor volume, mice were randomized using Easy stat software. Compound A (15 mg/kg or 40 mg/kg expressed as free base) was injected i.v. once a week over two weeks.
Preparation of the solutions for injection:
In a 100 mL flask, introduce 20 g of Cavitron™ W7HP5 and add around 75 mL of a solution water/0.9% NaCl (70/30, v/v). Stir for 15 minutes at room temperature. Then, make up the solution to a volume of 100 mL by adding the previous solution water/0.9% NaCl, while maintaining magnetic stirring. Weigh the necessary amount of‘Compound A, H2S04’ and dissolve it with the previous 20% w/v Cavitron™ W7H5 solution. Heat the whole at 60 °C under vigorous magnetic stirring until solubilisation of the components of the mixture is complete. Measure the pH of the solution obtained. Adjust the pH to 3 by adding drop by drop, either HC1 0.1N or NaOH 0.1N, depending on the concentration of Compound A. Stir the mixture at least for 1 hour. Filtrate the obtained solution with a 0.2 m m -filter.
A 20% w/v Cavitron™ W7H5 solution containing a dose of 4 mg/mL of Compound A was prepared following this procedure. A second solution containing a dose of 1.5 mg/mL of Compound A was also prepared by diluting further the previous solution with the 20% w/v Cavitron™ W7H5 solution.
Mice were monitored for tumor development and body weight three times a week and tumor size was measured using electronic calipers. Tumor volume was estimated by measuring the minimum and maximum tumor diameters using the formula: (minimum diameter) (maximum diameter)/2. The last day with all control animals still present in the study, tumor growth inhibition was calculated using the formula:
Median (DTV at Dx in treated group)
1 xlOO
Median (DTV at Dx in Control group) wherein‘DTV (Delta Tumor Volume) at Dx’ is calculated as follows:
TV at Dx - TV at Randomization
‘TV’ means‘Tumor Volume’.
Mice were sacrificed at the first measurement for which tumor volume exceeded 2000 mm or animal health deterioration. All experiments were conducted in accordance with the French regulations in force in 2018. SCID mice were maintained according to institutional guidelines.
Results
Compound A, formulated in a 20 % HR-b-cyclodextrin solution and administrated intravenously once a week for 2 weeks was shown to have antitumor activity at 15 mg/kg and 40 mg/kg on RS4;l l grafted female SCID mice (Figure 1). At the end of the study, at day 21, tumor growth inhibitions were 57.83% at 15 mg/kg and 75.52% at 40 mg/kg, with an exposure of 20463 ng.h/ml and 46509 ng.h/ml respectively. The Cmax increased dose proportionally from 14692 ng/ml to 23290 ng/ml (Table 1). Table 1: PK parameters measured for RS4;l l grafted female SCID mice after one i.v. treatment of‘Compound A, FT SOT formulated in a 20 % HR-b-cyclodextrin solution at 15 mg/kg and 40 mg/kg .
Figure imgf000032_0001
‘AUCt’ corresponds to the area under the observed blood concentration versus time curve from the time of administration to the last point.
No clinically relevant body weight loss due to treatment was observed (Figure 2) over the study and mice did not have other clinical signs including necrosis for most of the mice. In conclusion, based on body weight changes both dosing regimens of the cyclodextrin-based formulation were well tolerated.
EXAMPLE 8: Clinical Trial Protocol
A phase I, open label, non-randomised, non-comparative, multi-center study, was set up to evaluate Compound A intravenously administered, in patients with Relapse or Refractory Acute Myeloid Leukaemia, Non Hodgkin Lymphoma or Multiple Myeloma. Approximately 60 patients will be enrolled in the study. This study is designed in two parts: part one for dose escalation, part two for dose expansion. Primary objectives:
Determine the safety profile (including Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD(s)) and tolerability of Compound A in patients with Acute Myeloid Leukaemia (AML), Non Hodgkin Lymphoma (NHL) or Multiple Myeloma (MM) and the recommended phase II dose (RP2D(s)) according to safety, PK and preliminary efficacy results.
Secondary objectives:
- To determine the pharmacokinetic (PK) profile of Compound A in plasma and in urine.
- To assess the preliminary anti-tumour activity of Compound A using the appropriate response criteria for each evaluated population (AML, NHL, MM).
Test drug:
- Compound A will be administered via i.v. infusion via a central or peripheral venous line.
- Solution for infusion will be prepared using a 20 mL vials containing 150 mg of Compound A (expressed as free base) formulated with a HR-b-cyclodextrin as described in Example 5.
- Duration of infusion, based on preliminary Safety and PK data, could be adapted.
Dose allocation methodology:
A Bayesian Hierarchical Model (BHM), combined for all indications and guided by an escalation with overdose control (EWOC) method, will be used to guide dose escalation and estimate the MTD(s) based on the occurrence of DLT during Cycle 1.
Alternatively, an adaptative Bayesian Logistic Regression Model (BLRM) guided by an escalation with overdose control (EWOC) method, will be used to make dose recommendations based on the occurrence of DLT(s) during Cycle 1 and estimate the MTD(s)/RP2D(s) for the Compound A administered as a single agent. Treatment period:
The planned duration of treatment is until disease progression. Patients may be discontinued from treatment with the study drug earlier due to unacceptable toxicity and/or treatment is discontinued at the discretion of the investigator or the patient.
EXAMPLE 9: of the pH of
Figure imgf000034_0001
A bv addition of
NaOH to a HR-b-cvclodextrin solution
The objective of this study is to define the pH of precipitation of Compound A (hydrogen sulfate salt) from HR-b-cyclodextrin solution to better understand the risk of precipitation and select the pH of the drug product.
Preparation of solution containing HR-b-cyclodextrin and Compound A
Weigh 10 g of Cavitron™ W7H5 in a 50 mL flask. Add 26 g of water and then solubilize the Cavitron™ W7H5 under magnetic agitation. Carefully add 1.14 g of Compound A under magnetic agitation and then add 6.5 mL of water. Solubilize Compound A using magnetic agitation at 60 °C. Once totally solubilized, cool down the solution at room temperature then rinse the upper edges of the flask with 0.5 mL of water. The total amount of water added is 35 mL.
PH adjustment using 0.5M NaOH solution
Slowly add 0.5M NaOH solution under continuous agitation (add 100 pL at each addition step) up to a precipitation is visually observed. The experiment was performed in duplicate. The precipitated solid is separated and dried to be analyzed by RMN, XRPD, XRF, and HPLC.
Results
Drug precipitation was observed at pH 4.27. The volume of added NaOH corresponded to 5 % of final bulk solution volume when reaching pH 3.0 and corresponded to 6 % of final bulk solution volume when reaching pH 4.27.
Based on this result, the pH of the pharmaceutical composition could be increased up to
4.3. The NMR and XRPD results showed that Compound A precipitated as free base in amorphous form in the presence of HR-b-cyclodextrin at a molar ratio of 1 : 1.4. The HPLC result suggested that the precipitate was composed by 25 % w/w Compound A without the presence of additional impurities, which is in agreement with Compound A:HP-P-cyclodextrin ratio found by NMR.

Claims

1. A solid pharmaceutical composition comprising Compound A which is 5-(5- chloro-2-{ [(35,)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(l /)-yl]carbonyl} phenyl )-/V-(5-cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 H- pyrrole-3-carboxamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
2. A solid pharmaceutical composition according to claim 1, wherein Compound A is in the form of the hydrochloride salt.
3. A solid pharmaceutical composition according to claim 1, wherein Compound A is in the form of a hydrogen sulfate salt.
4. A solid pharmaceutical composition according to any of claims 1 to 3, wherein the cyclodextrin is a sodium sulfobutylether-P-cyclodex trine (SBE- b-cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin).
5. A solid pharmaceutical composition according to claim 4, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is at least 5 : 1.
6. A solid pharmaceutical composition according to claim 5, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is 5 : 1.
7. A solid pharmaceutical composition according to any of claims 4 to 6, wherein the HP- b-cyclodextrin is Cavitron™ W7HP5.
8. A solid pharmaceutical composition according to any of claims 4 to 6, wherein the HP- b-cyclodextrin is Kleptose™ HPB.
9. A solid pharmaceutical composition according to any of claims 1 to 8, further comprising one or more pharmaceutically acceptable excipients.
10. A solid pharmaceutical composition according to any of claims 1 to 8, comprising at least one pharmaceutically acceptable excipients selected from glucose, mannitol, sucrose, trehalose and sorbitol.
11. A solid pharmaceutical composition according to any of claims 1 to 10, which is a lyophilisate.
12. A pharmaceutical composition comprising Compound A which is 5-(5-chloro-2- { [(35,)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(lH)-yl]carbonyl}phenyl)- V-(5- cyano- 1 ,2-dimethyl- l//-pyrrol-3-yl)-/V-(4-hydroxyphenyl)- 1 ,2-dimethyl- 1 //-pyrrole-3- carboxamide, or a pharmaceutically acceptable salt thereof, a cyclodextrin and one or more solvents.
13. The pharmaceutical composition according to claim 12 wherein the solvent is an aqueous buffer or water, and more particularly water.
14. The pharmaceutical composition according to claim 12 or 13, wherein Compound A is in the form of the hydrochloride salt.
15. The pharmaceutical composition according to claim 12 or 13, wherein Compound
A is in the form of a hydrogen sulfate salt.
16. The pharmaceutical composition according to claim 15, having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5.
17. The pharmaceutical composition according to any of claims 12 to 16, wherein the cyclodextrin is a sodium sulfobutylether^-cyclodextrin (SBE- b-cyclodextrin) or a hydroxypropyl- b-cyclodextrin (HP- b-cyclodextrin).
18. The pharmaceutical composition according to claim 17, wherein the HP- b- cyclodextrin is Cavitron™ W7HP5 or Kleptose™ HPB.
19. The pharmaceutical composition according to claim 18, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is at least 5 : 1.
20. The pharmaceutical composition according to claim 19, wherein the molar ratio between the HP- b-cyclodextrin and Compound A is 5 : 1.
21. The pharmaceutical composition according to any of claims 17 to 19, wherein the HP- b-cyclodextrin is Cavitron™ W7HP5.
22. The pharmaceutical composition according to any of claims 17 to 19, wherein the HP- b-cyclodextrin is Kleptose™ HPB.
23. The pharmaceutical composition according to any of claims 17 to 22 having a concentration of 200 mg/mL of HP- b-cyclodextrin.
24. The pharmaceutical composition according to any of claims 17 to 22 having a concentration of 20 mg/mL of Compound A, free base.
25. The pharmaceutical composition according to any of claims 12 to 24, further comprising a tonicity adjusting agent.
26. The pharmaceutical composition according to claim 25, wherein the tonicity adjusting agent is selected from glucose, mannitol, sucrose, trehalose and sorbitol.
27. The pharmaceutical composition according to claim 12 comprising‘Compound A, H2S04’, Cavitron™ W7HP5, and having a pH value comprised between 2.5 and 4.3, more particularly the pH value is comprised between 2.5 and 3.5.
28. The pharmaceutical composition according to claim 12 comprising‘Compound A, ThSCV, Cavitron™ W7HP5, water and glucose, and having a pH value comprised between 2.5 and 4.4, more particularly the pH value is comprised between 3.3 and 4.4.
29. The pharmaceutical composition according to any of claims 12 to 28, for parenteral administration.
30. The pharmaceutical composition according to claim 29, for infusion or intravenous injection.
31. A process for preparing a pharmaceutical composition according to claim 12 suitable for parenteral administration comprising the dissolution of a solid pharmaceutical composition as defined in claims 1 to 11 in water.
32. A process according to claim 31 comprising an additional step of dilution with a solution of 5% Glucose.
33. A process according to claim 31 or 32, wherein the dissolution takes place immediately prior to administration to the patient.
34. A method of modulating Bcl-2 receptor activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the composition according to any of claims 12 to 30.
35. A method of treating cancer, comprising administering to the subject a therapeutically effective amount of the composition according to any of claims 12 to 30.
36. A method according to claim 35, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small- cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
37. A method according to claim 36, wherein the cancer is selected from non- Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia.
38. A method according to any of claims 34 to 37, wherein the composition according to any of claims 10 to 24, is administered once weekly.
39. The pharmaceutical composition according to any of claims 12 to 30 for use as a medicament.
40. A pharmaceutical composition for use according to claim 39, wherein said use is in the treatment of cancer, in particular wherein cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
41. Use of solid pharmaceutical composition according to any of claims 1 to 11, for the preparation of a medicament to treat cancer.
42. The use according to claim 41, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemia, lymphomas, for example non-Hodgkin's B-cell lymphoma and diffuse large B-cell lymphoma, melanomas, malignant haemopathies, for example myelodysplastic syndrome, myelomas, for example multiple myeloma, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer, in particular non-Hodgkin's B-cell lymphoma, diffuse large B-cell lymphoma, multiple myeloma, myelodysplastic syndrome, chronic lymphoid leukaemias and acute myeloid leukaemia.
43. A combination comprising:
• a pharmaceutical composition according to any of claims 12 to 30, and
• one or more therapeutically active agents, for simultaneous, sequential or separate use.
PCT/EP2019/079644 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor WO2020089286A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP19801728.7A EP3873529A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
US17/288,721 US20210353633A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
EA202191144A EA202191144A1 (en) 2018-10-31 2019-10-30 COMPOSITION OF A BCL-2 INHIBITOR BASED ON CYCLODEXTRIN
SG11202103965TA SG11202103965TA (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
MX2021004864A MX2021004864A (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor.
CA3117511A CA3117511A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
JOP/2021/0079A JOP20210079A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
AU2019373373A AU2019373373B2 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a Bcl-2 inhibitor
CN201980070474.4A CN112912108A (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulations of BCL-2 inhibitors
CR20210210A CR20210210A (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor
KR1020217016354A KR20210102886A (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulations of BCL-2 inhibitors
BR112021007987-4A BR112021007987A2 (en) 2018-10-31 2019-10-30 cyclodextrin-based formulation of a bcl-2 inhibitor
PE2021000642A PE20211738A1 (en) 2018-10-31 2019-10-30 CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR
JP2021523227A JP2022506069A (en) 2018-10-31 2019-10-30 Bcl-2 inhibitor cyclodextrin-based formulation
PH12021550878A PH12021550878A1 (en) 2018-10-31 2021-04-20 Cyclodextrin-based formulation of a bcl-2 inhibitor
DO2021000073A DOP2021000073A (en) 2018-10-31 2021-04-21 CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR
CONC2021/0005221A CO2021005221A2 (en) 2018-10-31 2021-04-23 Cyclodextrin-based formulation of a bcl-2 inhibitor
IL282688A IL282688A (en) 2018-10-31 2021-04-27 Cyclodextrin-based formulation of a bcl-2 inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31
US62/753,164 2018-10-31

Publications (1)

Publication Number Publication Date
WO2020089286A1 true WO2020089286A1 (en) 2020-05-07

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/079644 WO2020089286A1 (en) 2018-10-31 2019-10-30 Cyclodextrin-based formulation of a bcl-2 inhibitor

Country Status (25)

Country Link
US (1) US20210353633A1 (en)
EP (1) EP3873529A1 (en)
JP (1) JP2022506069A (en)
KR (1) KR20210102886A (en)
CN (1) CN112912108A (en)
AR (1) AR116922A1 (en)
AU (1) AU2019373373B2 (en)
BR (1) BR112021007987A2 (en)
CA (1) CA3117511A1 (en)
CL (1) CL2021001018A1 (en)
CO (1) CO2021005221A2 (en)
CR (1) CR20210210A (en)
DO (1) DOP2021000073A (en)
EA (1) EA202191144A1 (en)
GE (1) GEP20237580B (en)
IL (1) IL282688A (en)
JO (1) JOP20210079A1 (en)
MX (1) MX2021004864A (en)
NI (1) NI202100031A (en)
PE (1) PE20211738A1 (en)
PH (1) PH12021550878A1 (en)
SG (1) SG11202103965TA (en)
TW (1) TWI738100B (en)
UY (1) UY38431A (en)
WO (1) WO2020089286A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023514A1 (en) 2020-07-31 2022-02-03 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
WO2022200444A1 (en) 2021-03-24 2022-09-29 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3n)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031673A1 (en) * 2013-07-23 2015-01-29 Les Laboratoires Servier Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
JP2003321364A (en) * 2002-05-07 2003-11-11 Eisai Co Ltd Antineoplastic agent-containing composition solubilized and stabilized with cyclodextrin
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031673A1 (en) * 2013-07-23 2015-01-29 Les Laboratoires Servier Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
WO2015011400A1 (en) 2013-07-23 2015-01-29 Les Laboratoires Servier Novel pyrrole derivatives, method for the production thereof and pharmaceutical compositions containing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications", 28 March 2011, JOHN WILEY & SONS, INC., article FÜSUN ACARTÜRK ET AL: "CYCLODEXTRINS AS BIOAVAILABILITY ENHANCERS", pages: 45 - 64, XP055666311, DOI: https://doi.org/10.1002/9780470926819.ch3 *
SAOKHAM ET AL., MOLECULES, vol. 23, 2018, pages 1161

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023514A1 (en) 2020-07-31 2022-02-03 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
WO2022200444A1 (en) 2021-03-24 2022-09-29 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3n)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

Also Published As

Publication number Publication date
CR20210210A (en) 2021-05-25
AU2019373373B2 (en) 2023-09-28
CA3117511A1 (en) 2020-05-07
JOP20210079A1 (en) 2023-01-30
TWI738100B (en) 2021-09-01
US20210353633A1 (en) 2021-11-18
CL2021001018A1 (en) 2021-11-26
PH12021550878A1 (en) 2021-10-18
AR116922A1 (en) 2021-06-30
AU2019373373A1 (en) 2021-05-20
MX2021004864A (en) 2021-08-11
GEP20237580B (en) 2023-12-25
DOP2021000073A (en) 2021-11-15
NI202100031A (en) 2021-08-24
EP3873529A1 (en) 2021-09-08
CO2021005221A2 (en) 2021-07-19
JP2022506069A (en) 2022-01-17
SG11202103965TA (en) 2021-05-28
IL282688A (en) 2021-06-30
PE20211738A1 (en) 2021-09-06
UY38431A (en) 2020-05-29
KR20210102886A (en) 2021-08-20
BR112021007987A2 (en) 2021-08-03
CN112912108A (en) 2021-06-04
EA202191144A1 (en) 2021-09-27
TW202031295A (en) 2020-09-01

Similar Documents

Publication Publication Date Title
AU2019373373B2 (en) Cyclodextrin-based formulation of a Bcl-2 inhibitor
JP5823093B2 (en) Low dose diclofenac and β-cyclodextrin formulation
JP2015145364A (en) Pharmaceutical compositions
BR112012033077B1 (en) pharmaceutical composition for intravenous administration, use of a pharmaceutical composition, and, kit
CA2522115A1 (en) A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid
JP2017533274A (en) Methotrexate formulation
JP6818019B2 (en) Injectable pharmaceutical composition of lefamulin
AU2003276689B2 (en) Liquid stable composition of oxazaphosphorine with mesna
CA3157999A1 (en) Injectable compositions of ursodeoxycholic acid
RU2804366C2 (en) Composition of bcl-2 inhibitor based on cyclodextrin
US20220008337A1 (en) Pharmaceutical liquid compositions of meloxicam
OA20228A (en) Cyclodextrin-based formulation of A BCL2 inhibitor.
JP2016508138A (en) Cabazitaxel composition
EA044714B1 (en) COMPOSITION OF BCL-2 INHIBITOR BASED ON CYCLODEXTRIN
US10342816B2 (en) Aqueous ophthalmic formulations based on azithromycin
CN111728940A (en) Pharmaceutical compositions containing taxane-cyclodextrin complexes, methods of manufacture, and methods of use
US20040202687A1 (en) Ciprofloxacin formulations and methods of making and using the same
EP4055005A1 (en) Liquid melphalan composition
US20230190737A1 (en) Stable liquid compositions of netupitant and palonosetron
JP2005520856A (en) Eplerenone formulation stable during storage
WO2018109731A1 (en) Pharmaceutical compositions of taxane and its derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19801728

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3117511

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021523227

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15618/1

Country of ref document: GE

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021007987

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019373373

Country of ref document: AU

Date of ref document: 20191030

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019801728

Country of ref document: EP

Effective date: 20210531

ENP Entry into the national phase

Ref document number: 112021007987

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210427